Capricor Therapeutics Inc (CAPR)

Currency in USD
10.240
-0.980(-8.73%)
Closed·
9.900-0.340(-3.32%)
·
Advertisement
CAPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.86810.950
52 wk Range
2.96040.370
Key Statistics
Prev. Close
10.24
Open
10.95
Day's Range
9.868-10.95
52 wk Range
2.96-40.37
Volume
4.78M
Average Volume (3m)
6.15M
1-Year Change
77.4697%
Book Value / Share
3.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CAPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.250
Upside
+166.11%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Capricor Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
5 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 27.250
(+166.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy25.00+144.14%-Upgrade11/11/2026
Oppenheimer
Buy54.00+427.34%-Maintain08/10/2026
Oppenheimer
Buy54.00+427.34%-Maintain17/09/2026
B.Riley
Buy21.00+105.08%-Upgrade14/09/2026
Piper Sandler
Buy25.00+144.14%-Upgrade01/09/2026

Capricor Therapeutics Inc Earnings Call Summary for Q3/2026

  • Capricor posted Q3 2026 loss of $0.73/share vs. $0.13 estimate; net loss widened to $42.7M from $24.6M year-over-year amid pre-launch spending.
  • Company holds $198.5M in cash and securities, sufficient for 12+ months of operations; no ATM share sales in 2026, reducing dilution concerns.
  • FDA review of lead therapy deramiocel for Duchenne muscular dystrophy ongoing, with target action date of Nov. 22, 2026; preparing independent launch.
  • San Diego GMP facility operational with 250-patient annual capacity; second floor expansion expected H1 2027 to support 2,000-2,500 patients yearly.
  • Workforce reduced 10% to align costs; ongoing arbitration with NS Pharma not expected to impede commercialization if approval secured.
Last Updated: 10/11/2026, 22:22
Read Full Transcript

Earnings

Latest Release
10/11/2026
EPS / Forecast
-0.73 / -0.13
Revenue / Forecast
-- / 41.71M
EPS Revisions
Last 90 days

Compare CAPR to Peers and Sector

Metrics to compare
CAPR
Peers
Sector
Relationship
P/E Ratio
−4.0x−1.6x−0.2x
PEG Ratio
0.09−0.040.00
Price/Book
2.8x2.1x2.6x
Price / LTM Sales
-111.4x2.8x
Upside (Analyst Target)
166.1%465.5%63.4%
Fair Value Upside
Unlock5.3%9.5%Unlock

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.22M17.57%114.63M
Other Institutional Investors
45.75M78.68%513.26M
Public Companies & Retail Investors
2.18M3.75%24.43M
Total
58.14M100.00%652.32M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nippon Shinyaku Co., Ltd.8.50%4,944,42955,476
BlackRock, Inc.7.13%4,145,06146,508

People Also Watch

209.67
ONTO
-2.51%
144.37
AXSM
-3.26%
1.970
TE
-7.51%

FAQ

What Is the Capricor Therapeutics (NASDAQ: CAPR) Share Price Today?

The Capricor Therapeutics stock price today is 10.240 USD.

What Stock Exchange Does Capricor Therapeutics (CAPR) Trade On?

Capricor Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Capricor Therapeutics?

The stock symbol (also called a 'ticker') for Capricor Therapeutics is "CAPR."

What Is the Current Capricor Therapeutics Market Capitalisation?

As of today, Capricor Therapeutics (NASDAQ: CAPR) market cap is 595.380M USD.

What Is Capricor Therapeutics's (CAPR) Earnings Per Share (TTM)?

The Capricor Therapeutics EPS is currently -2.65 (Trailing Twelve Months).

When Is the Next Capricor Therapeutics Earnings Date?

Capricor Therapeutics's next earnings report will be released on 11/03/2027.

Is CAPR a Buy or Sell From a Technical Analyst Perspective?

Based on today's Capricor Therapeutics moving averages and other technical indicators, the daily buy/sell signal for CAPR stock is Strong Buy.

How Many Times Has Capricor Therapeutics Stock Split?

Capricor Therapeutics has split 2 times. (See the CAPR stock split history page for full effective split date and price information.)

How Many Employees Does Capricor Therapeutics Have?

Capricor Therapeutics has 231 employees, based on their latest Companies House report.

What is the current trading status of Capricor Therapeutics (NASDAQ: CAPR)?

As of 13/11/2026, Capricor Therapeutics (CAPR) is trading at a share price of 10.240 USD, with a previous close of 10.240 USD. The stock has fluctuated within a day range of 9.868 USD to 10.950 USD, while its 52-week range spans from 2.960 USD to 40.370 USD.

What Is Capricor Therapeutics (CAPR) Price Target According to Analysts?

The average 12-month price target for Capricor Therapeutics is 27.250 USD, with a high estimate of 54 USD and a low estimate of 10.5 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +166.11% Upside potential.

What Is the CAPR Premarket Price?

CAPR's last pre-market stock price is 10.940 USD. The pre-market share volume is 111,320.000, and the stock has decreased by -0.280, or -2.500%.

What Is the CAPR After Hours Price?

CAPR's last after hours stock price is 9.900 USD, the stock has decreased by -0.340, or -3.320%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.